Tocilizumab treatment for new onset refractory status epilepticus.
Jin-Sun JunSoon Tae LeeRyul KimKon ChuSang Kun LeePublished in: Annals of neurology (2018)
We investigated the therapeutic potential of the interleukin-6 receptor inhibitor tocilizumab in 7 patients with new onset refractory status epilepticus (NORSE) who remained refractory to conventional immunotherapy with rituximab (n = 5) or without rituximab (n = 2). Status epilepticus (SE) was terminated after 1 or 2 doses of tocilizumab in 6 patients with a median interval of 3 days from the initiation. They had no recurrence of SE during the observation. However, 2 patients experienced severe adverse events related to infection during the tocilizumab therapy. Further prospective controlled studies are warranted to validate the efficacy and safety of tocilizumab in patients with NORSE. Ann Neurol 2018;84:940-945.
Keyphrases
- rheumatoid arthritis
- juvenile idiopathic arthritis
- rheumatoid arthritis patients
- disease activity
- diffuse large b cell lymphoma
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- mesenchymal stem cells
- chronic lymphocytic leukemia
- high resolution
- hodgkin lymphoma
- combination therapy
- free survival
- binding protein
- high speed